Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1521823 | 0.98 | CPB2 (0.41) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL11418503 | 0.98 | CPB2 (0.41) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL3428343 | 0.97 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL4726518 | 0.85 | CYP1A2 (0.45) | CPB2CPB1 | |
| SCHEMBL4727798 | 0.85 | CYP1A2 (0.45) | CPB2CPB1 | |
| Imidazole SCHEMBL11330122 | 0.84 | CPB2 (0.34) | CPB2CPB1 | |
| SCHEMBL1779971 | 0.83 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL1071999 | 0.83 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL5147283 | 0.81 | CPB2 (0.39) | CPB2CPB1 | |
| SCHEMBL18319699 | 0.78 | MTNR1A (0.40) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024351-A1 | TOPICAL COMPOSITION FOR DESTROYING, in vivo, AN EXTERNAL HYPERPLASTIC TISSUE, SUCH AS, BUT NOT LIMITED TO, A VIRAL SKIN LESION, SUCH AS, BUT NOT LIMITED TO, A VIRAL WART | SEPPER ALEXANDER (US) | 2024-01-25 | — | — | US | claimed |
| US-11730745-B1 | Kit and new method of treatment for skin basal cell and squamous cell carcinoma | SEPPER ALEXANDER (US) | 2023-08-22 | — | — | US | claimed |
| US-20230000999-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY | PARANG KEYKAVOUS (US) | 2023-01-05 | — | — | US | claimed |
| US-20220016244-A1 | PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION | RICHTER GEDEON NYRT. (HU) | 2022-01-20 | — | — | US | claimed |
| EP-3935128-A1 | CATIONIC COATINGS FOR IMPROVED NANOPARTICLE TRANSPORT IN A CARBONATE RESERVOIR | Saudi Arabian Oil Company (SA) | 2022-01-12 | — | — | EP | claimed |
| US-11078394-B2 | Cationic coatings for improved nanoparticle transport in a carbonate reservoir | SAUDI ARABIAN OIL COMPANY (SA) | 2021-08-03 | — | — | US | claimed |
| WO-2021134026-A2 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY | AJK PHARMACEUTICAL LLC (US) | 2021-07-01 | — | — | WO | claimed |
| US-20200283672-A1 | CATIONIC COATINGS FOR IMPROVED NANOPARTICLE TRANSPORT IN A CARBONATE RESERVOIR | SAUDI ARABIAN OIL COMPANY (SA) | 2020-09-10 | — | — | US | claimed |
| US-20200281968-A1 | PHYSICAL OPTIMIZATION BEVERAGE | COGNATE3 LLC (US) | 2020-09-10 | — | — | US | claimed |
| CN-108653238-A | A kind of lignin-histidine medicine-carried nano particles and preparation method thereof with pH responses | 北京林业大学 | 2018-10-16 | — | — | CN | claimed |
| WO-2001044499-A1 | MODIFIED LABELED COMPLEMENT COMPONENTS FOR IMMUNOASSAYS | DIAGEN CORPORATION (US) | 2001-06-21 | — | — | WO | claimed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | claimed |
| EP-0635301-A2 | Carbon-clad inorganic oxide particles with a polymer coating thereon | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-01-25 | — | — | EP | claimed |
| US-5182016-A | Liquid chromatography absorbers or adsorbers | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1993-01-26 | — | — | US | claimed |
| US-5158684-A | Additing thermally stable chelant | BETZ LABORATORIES, INC. | 1992-10-27 | — | — | US | claimed |
| EP-0448302-A2 | Carbon-clad inorganic oxide particles and the same with a polymer coating thereon | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1991-09-25 | — | — | EP | claimed |
| EP-0250559-A1 | PARENTERAL NUTRITION THERAPY WITH AMINO ACIDS | VEECH, Richard L. (US) | 1988-01-07 | — | — | EP | claimed |
| WO-1987003806-A1 | PARENTERAL NUTRITION THERAPY WITH AMINO ACIDS | VEECH RICHARD L | 1987-07-02 | — | — | WO | claimed |
| EP-0008171-B1 | HAIR TREATMENT COMPOSITION AND METHOD | UNILEVER PLC (GB) | 1981-11-11 | — | — | EP | claimed |
| EP-0008171-A1 | Hair treatment composition and method | UNILEVER PLC (GB) | 1980-02-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000999-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY | ARGLU1, SLC7A11, PNISR | CPB2 2747/4885CPB1 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.